Prime Highlights
- China’s Hansoh Pharmaceutical posted a 27% rise in net profit to 5.56 billion yuan for 2025, beating the market forecast of 4.97 billion yuan.
- Revenue climbed 22.6% to 15.03 billion yuan, driven by growth in innovative medicines and business development deals.
Key Facts
- Hansoh signed a licensing deal worth up to $1.45 billion with Roche for a colorectal cancer treatment in October 2025.
- Hansoh specialises in oncology, central nervous system, metabolic and autoimmune disease treatments.
Background
Financial results of China’s Hansoh Pharmaceutical Group for the year 2025 showed net profit growth that exceeded market predictions. The company’s net profit for the year ending December 2025 increased by 27% to 5.56 billion yuan. This is about 804 million dollars. The profit was much higher than market estimates, which were around 4.97 billion yuan.
Revenue for the year also climbed sharply, jumping 22.6% to 15.03 billion yuan. The growth was driven by a stronger push into innovative medicines and income from business development deals, as the company continued to move away from its older generic drug portfolio.
Hansoh specialises in drugs that treat oncology, anti-infective conditions, central nervous system diseases, metabolic diseases and autoimmune diseases. The company has been expanding its licensing agreements and building out its pipeline of new treatments at a time when Beijing’s centralised bulk buying programmes have put pressure on revenues from generic medicines across the industry.
One of the highlights of the year was a major deal with Swiss pharmaceutical giant Roche. In October, Hansoh signed a licensing agreement worth up to $1.45 billion with Roche for an investigational treatment targeting colorectal cancer and other solid tumours. The deal drew significant attention and underlined the growing international appetite for Chinese pharmaceutical innovation.
These results mirror a larger strategic pivot by Hansoh that is sighting on the target of rarer and higher-valued, innovative drugs as the firm’s goal to stay in business and grow in a market dominated by competition.
